Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILE: Ranibizumab Dosing for Myopic CNV
NCT03042871Phase 4Completed
- Sponsor
- Zhongshan Ophthalmic Center
- Start
- Apr 2015
- Primary completion
- Jul 2018
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in choroidal neovascularization (CNV), sponsored by Zhongshan Ophthalmic Center. Started Apr 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT03042871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042871.